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Cancer evolves dynamically as clonal expansions
supersede one another driven by shifting selective
pressures, mutational processes, and disrupted
cancer genes. These processes mark the genome,
such that a cancer’s life history is encrypted in the
somatic mutations present. We developed algo-
rithms to decipher this narrative and applied them
to 21 breast cancers. Mutational processes evolve
across a cancer’s lifespan, with many emerging late
but contributing extensive genetic variation. Subclo-
nal diversification is prominent, and most mutations
are found in just a fraction of tumor cells. Every tumor
has a dominant subclonal lineage, representingmore
than 50% of tumor cells. Minimal expansion of these
subclones occurs until many hundreds to thousands
of mutations have accumulated, implying the exis-
tence of long-lived, quiescent cell lineages capable
of substantial proliferation upon acquisition of en-
abling genomic changes. Expansion of the dominant994 Cell 149, 994–1007, May 25, 2012 ª2012 Elsevier Inc.subclone to an appreciable mass may therefore
represent the final rate-limiting step in a breast
cancer’s development, triggering diagnosis.INTRODUCTION
Age-incidence curves of most common epithelial cancers show
rapidly increasing rates after the 4th–5th decades of life. Classic
mathematical models of tumor development developed by
Armitage and Doll (Armitage and Doll, 1954; Hornsby et al.,
2007) suggested that 5–8 rate-limiting events are required to
generate such incidence patterns. Since these studies were
performed in the 1950s, we have learnt much about the biolog-
ical and genetic basis of cancer. In particular, evolution toward
cancer often occurs on a phenotypic spectrum of increasingly
disordered premalignant stages, as ‘‘hallmark’’ cellular pro-
cesses are cumulatively co-opted or ablated in the cancer cells
(Hanahan and Weinberg, 2011). Somatic mutation is the funda-
mental mechanism by which cancer cells suborn these path-
ways (Stratton et al., 2009), notwithstanding the contributions
of epigenetic changes, cues from the local microenvironment
and germline genetic variation.
Whole-cancer genomes sequenced to date carry thousands
to tens of thousands of somatic mutations (Chapman et al.,
2011; Ding et al., 2010; Ley et al., 2010; Pleasance et al.,
2010a, 2010b; Puente et al., 2011; Shah et al., 2009), the vast
majority of which probably have no biological relevance. The
accumulation of mutations in cancerous and precancerous cells
over time is increasingly recognized as a complex, dynamic
process. Carcinogenic exposures and DNA repair defects can
lead to sustained elevations in mutation rate; telomere attrition
and chromothripsis can drive massive genomic rearrangement
in catastrophic bursts (Bignell et al., 2007; Campbell et al.,
2010; O’Hagan et al., 2002; Stephens et al., 2011).
In the classic view of cancer development, those somatic
mutations conferring a selective advantage on the cell drive
successive waves of clonal expansion, with the fittest clone
coming to dominate the cellular compartment. Increasingly,
however, cancers are recognized to be mixtures of competing
subclones, based on analyses of cancers sampled within
a patient at different times (Ding et al., 2012; Shah et al., 2009),
from different sites (Campbell et al., 2010; Ding et al., 2010;
Yachida et al., 2010), at hypermutable genomic loci (Campbell
et al., 2008), or through single-cell isolation (Anderson et al.,
2011; Navin et al., 2011; Notta et al., 2011). Although these
studies imply the existence of genetic heterogeneity within
a tumor, fundamental questions remain about the dynamics of
Darwinian evolution in cancer, the biological relevance of sub-
clonal genetic variation and the relationship between mutational
processes and clonal expansion.
Here, we use newly developed bioinformatic algorithms
(Greenman et al., 2012) to reconstruct the genomic history of
21 breast cancers. Borrowing the concept of a ‘‘most-recent
common ancestor’’ from population genetics, we can divide
somatic mutations into those acquired before the last complete
selective sweep (and thus shared by all cancer cells within the
sample) and those subclonal variants that occurred after
the emergence of the common ancestor. We study the early
genomic evolution of the eventual cancer clone, quantify the
extent and dynamics of subclonal variation within the cancer
sample sequenced and explore changes in mutation signatures
over time. These findings have important implications for
our understanding of how breast cancers develop over the
decades between breast organogenesis and diagnosis in the
adult.
RESULTS
Inference of Cancer Genome Evolution
We sequenced 20 primary breast cancer samples to an average
30–40 coverage across each base in the genome. The sample
series includes four cases each of estrogen-receptor (ER)-
positive, HER2-positive, and BRCA2-positive breast cancer;
three cases of triple negative; and five cases of BRCA1-positive
breast cancer. In addition, we sequenced to 188-fold depth one
other ER-positive tumor with a distinctive mutator phenotype,
consisting of C>A, C>G and C>T mutations specifically in a
TpC context. As described in the companion paper to this
(Nik-Zainal et al., 2012, this issue of Cell), we identified a high-
confidence, validated set of base substitutions, insertions, anddeletions (indels); genomic rearrangements; and copy number
changes in the 21 cancers.
To develop the reasoning that underpins this paper, we start
with the tumor sequenced to 188-fold depth, PD4120a. At the
chromosomal scale, the cancer genome is hypodiploid, with
relatively few copy number changes (Figure 1A). To exploit
the considerable sequencing depth available for this tumor,
we modified the parameters of our somatic substitution algo-
rithm in order to identify subclonal mutations; those found in
only a fraction of tumor cells. In total, we identified 70,690
somatic substitutions genome-wide, including many in which
fewer than 5% of the reads across the base reported the variant
allele. That these are bona fide mutations is evidenced by the
dominance of the C>* mutations in a TpC context at all levels
of subclonality (Figures S1A and S1B, available online) and
a high rate of verification in a subset by targeted PCR and
pyrosequencing.
The mutations fall into well-circumscribed clusters when
displayed by the fraction of reads reporting the variant (Figure 1B
and Figure S1C). The major cluster of points occurs at a read
depth around 210, with about 35% of reads reporting each
variant. Because an estimated 70% of cells in the sample derive
from the cancer clone, this cluster represents those point muta-
tions found in all tumor cells on one copy of a diploid chromo-
some. By comparison, mutations from regions of copy number 1
show a lower overall read depth (because the copy number is
lower) but higher variant allele fraction (because there are no
reads from the deleted chromosome).
The genome has one triploid chromosomal region, 1q, which is
most likely to have arisen as a single gain of one whole chromo-
some arm, although we cannot formally exclude duplication of
both alleles with subsequent loss of one. Mutations occurring
on the relevant chromosomal arm before duplication would be
present on two of three copies (with an expected variant allele
fraction of 55%), whereas mutations occurring after the dupli-
cation would be present on only one copy. In fact, we find only
seven mutations on 1q predicted to have occurred before the
chromosome arm was duplicated, not one of which has the
signature of C>* mutations in a TpC context (Figure S1C). In
contrast, 1,250 mutations are found on 1q at single copy
number, of which 1,130 have this mutation signature, with the
spectrum of early (ploidy 2) and late (ploidy 1) mutations being
significantly different (p < 0.0001, chi-square test). Trisomy 1q
is one of the commonest copy number alterations seen in breast
cancer (Beroukhim et al., 2010; Bignell et al., 2010). Our data
indicate that, relative to point mutations, this driver cytogenetic
change occurred very early during the evolution of this particular
tumor. Furthermore, albeit with small numbers of informative
early mutations, the mutator phenotype was not evident before
the occurrence of trisomy 1q.
Modeling Clonal and Subclonal Mutation Clusters
Many of the mutations we identify are present at a lower propor-
tion of reads than we would expect for the ploidy and level of
normal cell contamination in the sample (Figure 1B). These are
subclonal mutations, found in only a fraction of the tumor cells.
A particularly striking feature of these mutations is that they
seemingly fall into distinct clusters.Cell 149, 994–1007, May 25, 2012 ª2012 Elsevier Inc. 995
Figure 1. Genomic Architecture of
PD4120a, a Breast Cancer Genome
Sequenced to 188-Fold Coverage
(A) Copy number profile of the sample, with the
upper panel showing the logR of intensity and the
middle panel showing the B allele fraction (BAF) of
germline heterozygous SNPs. Genomic segments
of constant logR and BAF value were identified by
the ASCAT algorithm (green lines). These were
interpreted to give estimated overall copy number
(purple lines) and copy number of the minor allele
(blue lines) across the genome (lower panel).
(B) Distribution of 70,690 somatically acquired
base substitutions according to the total number
of reads across that base (x axis) and the fraction
of those reads reporting the variant (y axis). Points
are colored according to the chromosome the
mutation derives from.
(C) Statistical modeling of the distribution of clonal
and subclonal mutations by a Bayesian Dirichlet
process. The empiric histogram of mutations is
shown in pale blue, with the fitted distribution as a
dark green line. Also shown are the 95% posterior
confidence intervals for the fitted distribution (pale
green area). Four separate clusters of mutations,
named A–D, are identified.
(D) Estimated number of mutations found in
clusters A–D, with the error bars representing the
95% posterior confidence intervals.These data imply that the population of tumor cells within this
breast cancer sample contains several discrete subclones, each
of which represents a certain fraction of tumor cells and contains
a certain number of substitutions (namely the size of the cluster).
To enable formal development of this concept, we explicitly
modeled the observed patterns of clonal and subclonal muta-
tions with a hierarchical Bayesian Dirichlet process (Dunson,
2010). Using this flexible approach, we model the mutations as
deriving from an unknown number of subclones, each of which
is present at an unknown fraction of tumor cells and contributes
an unknown proportion of all somatic mutations, with all the996 Cell 149, 994–1007, May 25, 2012 ª2012 Elsevier Inc.unknown parameters to be jointly esti-
mated in the model (Extended Experi-
mental Procedures).
The model performs well on simulated
data sets, recapturing the ‘‘true’’ under-
lying distribution of subclones accurately,
across variable numbers and sizes
of subclonal populations (Figures S2A–
S2C). We therefore applied this model to
mutations found in PD4120a (Figure 1C
and Figure S2D). This clearly shows four
distinct clusters of mutations, one set
found in all tumor cells (which we call
cluster D henceforth) and three clusters
of subclonal mutations, centered on
variant allele fractions of 5% (cluster A),
11% (cluster B), and 19% (cluster C).
From the model, we can generate esti-
mates of the number of mutations foundin each of these clusters together with 95% posterior confidence
intervals for the estimates (Figure 1D).
The model predicts that some 26,762 mutations (95% poste-
rior interval, 22,378–31,160) are found in all tumor cells in
PD4120a. The implication is that during the evolution of this
cancer, there was some ancestral cell that carried this comple-
ment of somatic mutations. Borrowing the term from population
genetics, we term this cell the ‘‘most-recent common ancestor’’
of the tumor, and its emergence demarcates the split between
mutations that are fully clonal and those that are subclonal.
Among the mutations acquired before the emergence of the
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Figure 2. Subclonal Genetic Variation in PD4120a
(A) Battenberg plots of allele fractions for phased parental
haplotypes for four chromosomes. Germline SNPs are
phased by imputation, with observed allele fraction for one
phased chromosomal copy plotted in blue and the other
in red.
(B) Phasing of mutations (stars) with adjacent germline
heterozygous SNPs (vertical lines) allows determination of
whether a mutation is on the retained or subclonally
deleted parental copy of a chromosome.
(C) Distribution of somatically acquired base substitutions
on chromosome 13 according to the total number of reads
across that base (x axis) and the fraction of those reads
reporting the variant (y axis). Points are colored according
to whether the mutation derives from the retained copy of
chromosome 13 (green points), the subclonally deleted
copy of chromosome 13 (brown points) or whether it could
not be phased with a nearby heterozygous SNP (black
points).most-recent common ancestor are several in cancer genes,
including TP53, PIK3CA, GATA3, MLL3, SMAD4, and NCOR1.
In addition, the trisomy 1q described above had occurred, as
well as an unbalanced t(1;22) translocation and a cluster of
chromothripsis rearrangements involving chromosomes 2, 4,
18, and 21 (Figure S2E).
Subclonal Loss of Multiple Chromosomes in PD4120a
The copy number profile for chromosome 13 in PD4120a reveals
that it is deleted in some, but not all, tumor cells (Figure 1A). The
logR values, whichmeasure total copy number, show decreased
intensity compared to diploid chromosomes but higher than
monosomic chromosomes. The allele fraction plot, which
reports the relative proportions of the two alleles for heterozy-
gous SNPs, shows similarly intermediate levels for chromosome
13. From these variables, we estimate that 68% of tumor cells
have one copy of chromosome 13 deleted (95% confidence
interval, 67%–69%). The same pattern is seen for 22q, indicatingCell 149,that the t(1;22) derivative chromosome has been
deleted in a similar fraction of cells.
Allele frequency plots for chromosome 7 also
appear slightly more widely distributed around
0.5 than other diploid chromosomes, associ-
ated with a concomitant small decrease in
logR levels overall for this chromosome (Fig-
ure 1A), suggesting that the chromosome is
lost in a minor fraction of tumor cells. With
data from the 1000 Genomes Project (1000
Genomes Project Consortium, 2010), it is now
possible to impute linkage of many germline
SNPs into parent-specific haplotype blocks.
We hypothesized that analysis of allele ratios
by haplotype rather than individual SNP would
draw out subtle deviations from the expected
fraction of 0.5 with substantially improved
statistical power anddeveloped abioinformatics
method to assess this (the ‘‘Battenberg’’ algo-
rithm; Extended Experimental Procedures).
Applying it to chromosome 3 demonstrates noevidence for subclonal variation in copy number, as parent-
specific allelic fractions in red and blue are superimposed at
0.5, as expected (Figure 2A). In contrast, for chromosome 7,
red and blue patches marking parent-specific haplotypes show
clear separation, indicative of subclonal deletion of the chromo-
some in a small fraction of tumor cells. Remarkably, when we
apply this analysis genome-wide, we find that 14 chromosomes
overall show statistically significant evidence for subclonal copy
number variation (Figure 2A and Figure S3A). For these other
regions, which include chromosomes 6, 8, 9, 11, 12, 14, and
15, the extent of separation is similar and less than that observed
for chromosome 7.
Chromosome 2 shows an interesting pattern of changes. The
logR values for ‘‘diploid’’ regions of chromosome 2, measuring
overall copy number, are clearly lower than those for chromo-
some 5 (average logR, 0.020 versus 0.161; p < 10308) but virtu-
ally the same as for chromosome 7 (average logR, 0.020 versus
0.017; Figure S3B), implying that chromosome 2 is subclonally994–1007, May 25, 2012 ª2012 Elsevier Inc. 997
deleted in a similar proportion of cells to chromosome 7.
However, the haplotype-specific phasing analysis described
above confirms that the allele fraction at ‘‘diploid’’ regions of
the chromosome is exactly balanced at 0.5 (Figures S3A and
S3B). The implication therefore is that chromosome 2 is subclo-
nally deleted in PD4120a, but both parental copies have been
lost in an exactly balanced proportion of cells.
In summary, these analyses indicate subclonal deletion of
chromosome 13 in 68% of tumor cells. There is also evidence
for loss of chromosome 7 in a smaller fraction of cells, and for
losses of other chromosomes, including 6, 8, 9, 11, 12, 14, 15,
18, and 21 in an even smaller proportion. Finally, there is
convincing evidence that both parental copies of chromosome
2 have been lost in exactly equal proportions.
Integrating Subclonal PointMutations andCopyNumber
Changes
As discussed above, there is a cluster of 15,600 subclonal
point mutations found at a variant allele fraction of19% (cluster
C). Because this variant allele fraction ismore than half that of the
fully clonal mutations, each of thesemutations is present in more
than 50% of tumor cells. Consider any two of these mutations.
By the so-called ‘‘pigeonhole principle,’’ there must be at least
one tumor cell that contains both mutations, because there is
no way to apportion two lots of > 50% to completely separate
subsets. Therefore, the two variants must be collinear on the
phylogenetic tree. If this reasoning applies for any two such
mutations at > 50%, then it applies to all such mutations en
bloc. Furthermore, if one such mutation is found in a strictly
greater fraction of cancer cells than another such mutation,
then it must have occurred earlier than the other. Applying these
deductions to PD4120a, it follows that the mutations found in
cluster C are all on the same branch of the phylogenetic tree,
together with the subclonal deletion of chromosome 13. Further-
more, because the deletion is found in a larger proportion of
cells, it must have occurred earlier during the cancer’s evolution
than cluster C mutations.
We can directly test the veracity of this reasoning. Because we
reason that the deletion of 13 occurred before subclonal muta-
tions in cluster C, we predict that those subclonal mutations
could only involve the retained copy of chromosome 13. Many
somatic mutations will be sufficiently close to heterozygous
germline SNPs that individual sequencing read pairs will span
both, thus allowing the mutation to be ‘‘phased’’ with the SNP
(Figure 2B). Of the 2,171 mutations on chromosome 13, we
were able to phase 756 (35%) with a nearby heterozygous
SNP, thus unambiguously determining whether the mutation
occurred on the parental copy of chromosome 13 that was sub-
clonally deleted or on the retained copy (Figure 2C). We find
a cluster of mutations on the retained copy of chromosome 13
at a variant allele frequency of 48% (green points, Fig-
ure 2C)—this represents fully clonal mutations (cluster D). We
also see a cluster of mutations from the deleted copy of chromo-
some 13 at 15% (brown points), denoting ancestral mutations
subsequently deleted in 68% of tumor cells. A third distinct
cluster of mutations is evident at 25% of reads, the equivalent
of cluster C. All of these, as predicted, are phased with the
retained copy of chromosome 13.998 Cell 149, 994–1007, May 25, 2012 ª2012 Elsevier Inc.This approach is also informative for the other subclonally
deleted chromosomes. For mutations on the retained copy of
chromosomes 6, 7, 8, and 11, we find clusters A–D as for non-
subclonal diploid chromosomes (Figure 3A and data not shown).
For mutations on the parental copies of chromosomes 6 and
7 that are subclonally deleted, cluster B is completely lost,
whereas the others remain unchanged. This demonstrates that
virtually all mutations in cluster B are on a separate phylogenetic
branch from mutations in cluster C. Furthermore, the subclonal
deletion of chromosome 6 and 7must be collinear with themuta-
tions in cluster B. The same patterns and reasoning apply to
chromosome 8, 11, 12, 14, 15, 18 and 21. For chromosome 2,
we find that cluster B is abolished on both parental copies of
the chromosome. This confirms the observation from the logR
values that both copies of chromosome 2 are subclonally
deleted (Figure S2B) and moreover places these deletions on
the same branch as the mutations in cluster B.
In summary, these data indicate that the subclonal deletion of
chromosome 13 and the mutations in cluster C are on the same
branch of the phylogenetic tree, with del13 occurring first. On
a separate branch of the tree from this dominant subclone, we
find all the mutations in cluster B, together with subsequent
subclonal deletion of chromosomes 2, 6, 7, 8, 9, 11, 12, 14, 15,
18, and 21.
Phasing Pairs of Subclonal Somatic Mutations
We can also attempt to phase any two somatic mutations that
are sufficiently close together to be spanned by single read pairs.
We recognize two informative scenarios. The two mutations
could arise in completely independent subclones, in which
case reads could report either variant alone but never the two
together (Figure S4A). Alternatively, one mutation could occur
as subclonal evolution in a cell that already contains the other
mutation, in which case we would see reads that report the
earlier variant only as well as reads that report both variants
together (Figure S4B). It is only valid to identifymutually exclusive
mutation pairs in chromosomes that are haploid in the tumor,
and we do indeed find 17 such pairs (Figure 3B and Figure S4C).
Genome-wide, we also identify 76 examples of sub-subclonal
evolution occurring on the same allele as a pre-existent subclo-
nal mutation (Figure 3C, and Figure S4D). Strikingly, there are no
examples of sub-subclonal evolution at 9%–12% variant allele
fraction (cluster B) occurring in conjunction with a mutation
at > 16% allele fraction (cluster C), confirming that mutations in
cluster B fall on a separate phylogenetic branch from those in
cluster C.
These data also indicate that cluster A, the set of mutations at
a variant allele fraction 5%, is likely to contain several discrete
subclones. Some of these variants are clearly subclonal to
cluster C and others subclonal to cluster B, as shown in Fig-
ure 3C. However, most are not derived from cluster B, because
the peak for cluster A is largely unchanged for the parental copy
of chromosome 7 that is subclonally deleted (Figure 3A). Muta-
tions in cluster A frequently fell in mutually exclusive subclones
(Figure 3B) and hence on different branches of the phylogenetic
tree. It is therefore probable that some or evenmost of the cluster
A mutations represent a third branch from the most-recent
common ancestor. In support of this is a pair of cluster A
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Figure 3. Reconstructing the Evolution of PD4120a
(A) Distribution of clonal and subclonal mutations phased onto specific chromosomes. The empiric histogram of mutations is shown in pale blue, with the fitted
distribution and posterior intervals as dark green lines.
(B) Allele fractions for pairs of subclonal mutations that are found on separate branches of the phylogenetic tree, by virtue of no sequencing read evincing both
mutations together. Error bars represent the 95% confidence intervals for the observed fractions.
(C) Allele fractions for pairs of subclonal mutations found in the same subclone, where one occurred temporally later than the other. Error bars represent the
95% confidence intervals for the observed fractions.
(D) Reconstruction of the phylogenetic tree for PD4120a. The thickness of the branches reflects the proportion of tumor cells comprising that lineage. The length
of the branches reflects the number of mutations specific to that lineage.
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mutations, both of which phase with the subclonally deleted
copy of chromosome 13, and hence cannot be placed on the
del13 branch, but are mutually exclusive with one another
(Figure S4E).
A Phylogenetic Tree for PD4120a
With these observations, we can integrate the subclonal chro-
mosome-scale losses with the subclonal point mutations to
reconstruct how the tumor has evolved (Figure 3D). In one
branch of the phylogenetic tree, there has been loss of chromo-
some 13 and subsequent acquisition of cluster C mutations. The
other branch of the phylogenetic tree contains the cluster B
mutations and sub-subclonal losses of multiple chromosomes,
including both parental copies of chromosome 2. Because
homozygous deletion of chromosome 2 in a diploid cell is frankly
implausible, the most likely model is that a sub-subclone of the
cluster B subclone has become tetraploid, presumably through
an endoreduplication event. It has subsequently lost one of the
four copies of chromosomes 6, 8, 9, 11, 12, 14, 15, 18, and 21.
In addition, both copies of the same parental chromosome 7
have been lost, and one of each parental copy of chromosome
2 has been lost. From this model, we estimate that the subclone
with mutations in cluster C represent 65% of tumor cells, cluster
B represents 18% of tumor cells, and the tetraploid subclone
represents 14% of tumor cells. Mutations in cluster A account
for 14% of tumor cells. If many of these do fall on a third branch
of the phylogenetic tree, the three branches would neatly
account for all descendants of the most-recent common
ancestor because the 14% of tumor cells in cluster A, the 68%
with deletion 13, and the 18% of tumor cells in cluster B together
add up to 100%. This phylogenetic tree explains all data
observed for PD4120a.
Timing Chromosomal Evolution in 20 Breast Cancer
Genomes
Chromosomal instability, the gains and losses of whole chromo-
somes or chromosome arms, is a well-recognized feature of
breast cancer cells probably caused by missegregation of chro-
mosomes during cell division (Burrell et al., 2010). As outlined
above, for genomic regions that have increased in copy number,
we can estimate the timing of the duplication event by comparing
the proportion of mutations at ploidy 1 and ploidy 2 (Greenman
et al., 2012). Among the 20 breast genomes sequenced to 30-
to 40-fold depth, 16 had informative genomes for timing chromo-
somal gains (Figure 4). Broadly, the data suggest that the onset
of large-scale chromosomal gains did not begin across these
genomes until after at least 15%–20% of point mutation time
had elapsed but thereafter continued steadily in many tumors.
The implication is that chromosomal instability is not usually
the earliest source of mutation in breast cancer evolution, but
is a common and on-going process in later stages.
A related phenomenon is that of whole-genome duplication,
caused by a single event of cytokinesis failure, endoreduplica-
tion, or fusion of two diploid cells. Ten of the tumors studied
here show evidence for such an event, inferred from the homo-
geneity of the distribution of early and late mutations across
the genome (Figure 4 and Figure S5A). In general, such endore-
duplication was a late event in this series, occurring after more1000 Cell 149, 994–1007, May 25, 2012 ª2012 Elsevier Inc.than 50% of point mutation time had elapsed and often following
many preceding single chromosome losses and gains.
Five informative tumors had genomic amplifications of known
cancer genes, three involving ERBB2 and one each involving
MYC and CCND1. In four of the five cases, no mutations were
present on all copies of the amplified segment, even allowing
for the one patient where both parental copies of the locus
contributed to the amplification (Figures S5B and S5C). There-
fore, the first rearrangement driving the genomic amplification
presumably occurred early in the evolution of these cancers.
Interestingly, however, all amplifications showed multiple muta-
tions at several discrete stages of ploidy intermediate between
all copies and only one copy of the amplified region (Figures
S5B and S5C). These mutations must have accumulated after
the amplification had begun, because they do not involve all
copies, but before the amplification was complete, because their
ploidy is more than 1. Coupled with the fact that such mutations
were observed at several discrete levels of ploidy, these data
suggest that the genomic rearrangements driving the amplifica-
tions in these patients were acquired over a relatively protracted
period of molecular time. This pattern is different to mechanisms
of genomic amplification such as breakage-fusion-bridge or
double minute chromosomes, where amplification can occur
rapidly and even exponentially over a few cell cycles (Bignell
et al., 2007; Campbell et al., 2010; Stephens et al., 2011).
Changing Spectrum of Mutations over Time
In addition to timing when chromosomal gains occur, we can
compare the spectrum of point mutations acquired early, before
the copy number gain (ploidy 2), and late, after the gain (ploidy 1)
(Pleasance et al., 2010a). Fourteen of the genomes had sufficient
numbers of early and late mutations to enable statistical com-
parison of the mutation spectrum over time (Figure 5A). Of these,
11 had statistically significant differences in spectrum between
mutations acquired early and late, with many patients showing
a strikingly different profile.
The most consistent pattern is that C>T transitions constitute
a higher proportion of early mutations than of latemutations, with
10/14 genomes showing a statistically significant decrease
in C>T ratios after chromosome gains. C>T transitions are
frequently caused by spontaneous deamination of methylated
cytosine to thymine. However, we find that, in general, the
decreased proportion of C>T mutations over time applies
equally to other contexts as to those at CpG dinucleotides
(Figure S6).
In the companion paper to this one (Nik-Zainal et al., 2012), we
show that many breast cancer genomes have distinctive muta-
tion processes, from which a nonnegative matrix factorization
algorithm identified five separate signatures. By classifying
whether mutations were early clonal (ploidy > 1), late clonal
(ploidy = 1) or subclonal (ploidy < 1) in regions of copy number
gains, we could assess the relative contributions of these five
processes at different times during a cancer’s evolution. In
8 patients, sufficient numbers of mutations were present in
such regions to generate a stable solution (Figure 5B). This
confirms that C>T mutations at CpG dinucleotides, termed
‘‘signature A,’’ contributes a large proportion of the early muta-
tions in these cancers, and relatively few late in the evolution of
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were also significantly over-represented among late mutations
than early events (odds ratio, 1.9; p < 0.0001).
Taken together, these data indicate that the mutational forces
fashioning the breast cancer genome vary over time. C>T transi-
tions, both at CpG dinucleotides and in other sequence
contexts, play a significant role in the early acquisition of
mutations, accounting for up to 40% of mutations acquired
before chromosomal gains. To some extent, the profile of base
changes seen among many of the early breast cancer variants
is a default mutation spectrum, closely mirroring that seen in
tumor types such as blood, pancreatic, and brain cancers
(Greenman et al., 2007; Jones et al., 2008; Papaemmanuil
et al., 2011; Puente et al., 2011) and indeed in germline nucleo-
tide substitutions (Hwang and Green, 2004). The lower propor-
tional contribution of C>T transitions among late mutations is
most likely caused by an increase in the rate of other mutation
types because tumor-specific signatures account for much of
the variation between early and late mutations. Intriguingly, we
find that there are several mutation signatures at play in many
of these patients, contributing varying proportions of mutations
and with onset at different times during cancer evolution. The
implication therefore is that in most breast cancers, the mutation
rate increases in more advanced stages of tumor development,
driven by distinctive, cancer-specific mutational processes.
These processes continue past the emergence of the most-
recent common ancestor, driving subclonal diversification within
the tumor.
Timing Kataegis, Localized Clusters of Mutations
In the companion paper to this one (Nik-Zainal et al., 2012), we
describe localized clusters of C>T and C>Gmutations occurring
in a TpC context closely associated with genomic rearrange-
ments, which we termed kataegis. The presumption here is
that an individual cluster of mutations occurs in a single event
because of the close association with rearrangements and the
fact that there is a strong strand bias within a cluster. Although
the mutations within each cluster might occur simultaneously,
however, the relative timing of different clusters of kataegis is
not clear.
In PD4103a, there are many clusters of kataegis mutations
genome-wide. Interestingly, within the amplicon involving
regions of chromosomes 10, 11, and 12, we find that these clus-
ters occur at several different levels of ploidy (Figure 5C). For
example, on chromosome 12, there are several such events
found at variant allele fraction of 0.8 or higher in association
with rearrangements that demarcate large copy number
changes. These must have occurred early in the genesis of the
amplicon and then themselves been amplified by subsequent re-
arrangements. Interestingly, there is also a cluster at an allele
fraction of 0.4 and several at allele fractions < 0.1. These must
have occurred later in the genesis of the amplicon. In addition,
rearrangements in PD4103a outside this amplicon are also
associated with kataegis, such as a deletion of TP53 (Figure 5C).
The implication is that these clusters of mutations have not all
occurred in a single event.
The other patient with particularly high numbers of these clus-
ters, PD4107a, shows a somewhat different pattern. Here, the
kataegis mutations are found specifically in association witha chromothripsis event on chromosome 6 and are all at the
same level of ploidy. Thus, it seems very likely that both the
chromothripsis and kataegis mutations did occur in the same
catastrophic event. Nonetheless, elsewhere in this patient, there
are other rearrangements with adjacent kataegis clusters, again
arguing that this process can occur recurrently during the evolu-
tion of a breast cancer.
Dominant Subclones Are Always Present in Breast
Cancers
In PD4120a, the high sequencing depth enables us to infer the
existence of several subclonal expansions. For the 20 genomes
sequenced at 30- to 40-fold coverage, there is a measurable
probability that a sufficient number of reads will report a subclo-
nal variant to allow our algorithm to call the mutation. We esti-
mated this probability by using a statistical resampling method
known as bootstrapping (Extended Experimental Procedures).
On average for the 20 genomes, we have an approximately
90% chance of detecting a fully clonal mutation, a 60% chance
of detecting a mutation found in 50% of tumor cells, and a 5%
chance of detecting a mutation in 25% of tumor cells (Fig-
ure S7A). For 19 of the genomes reported here, 150–300
somatic substitutions were independently verified by PCR and
deep pyrosequencing on the 454 platform, giving accurate esti-
mates of the variant allele fraction for these mutations. For four
samples in which exome pull-down and sequencing was also
performed, the empiric distributions of subclonal mutations
called in the original genome and subsequently validated by
deep pyrosequencing or exome pull-down are very similar
(Figure S7B).
We therefore applied the Bayesian Dirichlet process described
earlier to the deep sequencing data, adding correction for the
sample-specific sensitivity for detecting mutations at different
levels of subclonality (Figures 6A and 6B and Figure S7C). We
find subclonal point mutations in all samples studied and indeed
the estimated number of these genome-wide is, for most
samples studied, more than the number of fully clonal mutations
(Figure 6A). As for PD4120a, we always find evidence for a domi-
nant subclonal lineage, comprising mutations found in 50%–
95% of tumor cells, which the pigeonhole principle dictates
must all be on the same branch of the phylogenetic tree. The
patterns and distribution of this subclonal variation show diver-
sity across the genomes, with some samples composed of
a broad range of subclones at differing fractions of tumor cells
(PD4088a, PD3905a, and PD4199a) and others showing fewer,
more distinct subclonal expansions (PD4116a, PD4005a, and
PD4085a). Overall, however, by the arguments above, all show
a single dominant lineage of subclonal and sub-subclonal
expansions within the population of cancer cells.
We can also apply the ‘‘Battenberg’’ analysis used for
PD4120a, in which we phase haplotypes of germline heterozy-
gous SNPs, to investigate subclonal copy number gains and
losses in the other 20 genomes (Figure 6C). Again, we find
considerable diversity in the frequency and patterns of subclonal
regional variation. Some samples, such as PD4088a and
PD4248a, showed very little subclonal copy number varia-
tion, but in other genomes, such as PD3851a, PD4085a, and
PD4116a, the vast majority of the genome varies in copy numberCell 149, 994–1007, May 25, 2012 ª2012 Elsevier Inc. 1003
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The cancer evolves through acquisition of driver mutations
(black stars), which produce clonal expansions. These
driver mutations occur only infrequently in long-lived line-
ages of cells, which passively accumulate manymutations
without expansion.among different subclones within the cancer. Among these
genomes, there is also diversity in the number of distinct sub-
clones evident by this analysis. For example, PD4192a shows
strong evidence on the Battenberg analysis for a subclone of
40%–50% of tumor cells with regional differences in copy
number from other subclones across 10–12 chromosomes.
Interestingly, this is matched by a discrete peak of point muta-
tions in 40%–50% of tumor cells (Figure S7C). In contrast,
many other genomes, such as PD4086a and PD3890a, show
evidence for several distinct levels of subclonality across the
genome. For three of these samples, we can apply similar(B) Distribution of clonal and subclonal mutations for three representative cancers. The empiric his
distribution and 95% posterior intervals as dark green lines.
(C) Subclonal copy number variation for the 20 breast cancer genomes, estimated by using the Batt
mated copy number, and segments are colored by whether they show no subclonal variation (gray) or
region (green to yellow to brown).
Cell 149, 9reasoning as used for PD4120a to reconstruct
the phylogenetic tree of the cancer (Figure S8).
In summary, these data indicate that a con-
siderable proportion of somatic genetic varia-
tion in these 20 genomes is found in only
a fraction of tumor cells. There is heterogeneity
among different cases, but as a general rule,
there is always a dominant subclonal lineage
separated from the most-recent common
ancestor by several hundreds to thousands of
mutations.
DISCUSSION
A Model of Breast Cancer Development
From the analyses described here, we can begin
to understand the dynamics of breast cancer
development (Figure 7). A key landmark in this
evolution is the appearance of the most-recent
common ancestor—the cell that has the full
complement of somatic mutations found in all
tumor cells. All extant cancer cells in the sample
analyzed can trace a genealogy back to the
fertilized egg through this common ancestor,
and its emergence demarcates the split in the
phylogenetic tree from the shared trunk to the
branches of divergent subclones. Our data
consistently indicate that the most-recent
common ancestor appeared surprisingly early
in molecular time, or, expressed another way,
much of molecular time is spent driving subclo-
nal diversification and evolution among thenascent cancer cells. This is different to what is observed for
acute myeloid leukemia, where the proportion of mutations
that are subclonal is relatively small (Ding et al., 2012).
Before the appearance of the most-recent common ancestor,
much oncogenic genetic change has accumulated in the lineage.
Many of the tumors studied here have several driver mutations
that are found in all tumor cells—all PIK3CA and TP53mutations,
all ERBB2, MYC, and CCND1 amplifications, all somatic loss
of the wild-type BRCA1 and BRCA2 alleles among these 21
cancers can be placed unequivocally on the shared trunk of
the phylogenetic tree. Chromosomal instability appears intogram of mutations is shown in pale blue, with the fitted
enberg algorithm. The height of each bar reflects the esti-
the estimated frequency of the minor subclone at the given
94–1007, May 25, 2012 ª2012 Elsevier Inc. 1005
many of the tumors from about 15%–20% of the way through
molecular time and has an on-going impact thereafter, even
beyond the appearance of the most-recent common ancestor.
This results in the clonal acquisition of many recurrent abnor-
malities, such as gains of 1q and 8q and losses of 17p, and
considerable divergence among subclones of the cancer in their
large-scale chromosomal composition. Like chromosomal insta-
bility, other cancer-specific point mutational processes materi-
alize during the tumor’s development, having considerable
impact on the number and patterns of late mutations.
Several profound insights into the patterns and dynamics
of subclonal evolution, occurring after the appearance of the
most-recent common ancestor, can be drawn from these 21
breast cancers. All of the tumors contained a dominant subclonal
lineage, accounting for more than 50% of cancer cells in the
sample and carryingmany hundreds or thousands of point muta-
tions. There is no a priori reason why a cancer should have such
a dominant subclone, nor why the phylogenetic branch should
carry so many mutations. The one unifying factor for all these
tumors is, rather obviously, that they have been diagnosed: in
other words, they are sufficiently large to be palpable or seen
on amammogram. In a breast cancer of typical size, 10 cm3 say,
the expansion of a subclone that ultimately constitutes 60% of
tumor cells will contribute 6 cm3 to the tumor bulk, assuming
stromal contamination and cell size are proportionate. Such
a significant fraction of a tumor’smass is likely to have a substan-
tial impact on whether a lesion is clinically detectable or not.
The implication, therefore, is that expansion of a dominant
subclonal lineage is the final rate-limiting step in the develop-
ment of breast cancer, triggering diagnosis. Two important
observations underpin this logic. First, the dominant subclone
is separated from the most-recent common ancestor by many
hundreds to thousands of point mutations, often more than the
set of mutations shared by all cancer cells. Second, there is
minimal evidence of significant clonal expansion before the
accumulation of all mutations in the dominant subclone. This
is particularly clearly demonstrated with the high sequence
coverage for PD4120a. The dominant subclone here has some
15,600 mutations found in 65% of tumor cells, with very few
subclonal mutations found in more than 65% of cells. The event
triggering the expansion of this subclone, presumably a somatic
mutation, must therefore be rate limiting in the sense that Armit-
age and Doll (1954) use, because so many mutations stack up
before the subclone begins proliferation.
Thus we glimpse amodel of long-lived, but sparse, lineages of
cells passively accumulating mutations until provoked into
a major quest for tumor dominance. It is only when this subclone
has grown sufficiently populous that the tumor mass becomes
clinically detectable. For the tumors studied here, the number
of mutations acquired after the split from the most-recent
common ancestor in the lineage that becomes the dominant
subclone is often similar to or more than the number acquired
before the split, a striking finding given that several driver muta-
tions are already present in the common ancestor. Our model
has an obvious similitude with the concept of cancer stem
cells—infrequent, self-renewing, metabolically quiescent cells
capable of reconstituting a tumor (Anderson et al., 2011; Notta
et al., 2011; Visvader and Lindeman, 2008).1006 Cell 149, 994–1007, May 25, 2012 ª2012 Elsevier Inc.The cancer genome is like a palimpsest, an ancient parchment
that was frequently reused, each time retaining traces of what
had previously been written. The interplay of point mutations,
chromosomal gains and losses, and clonal expansions, acquired
in a given temporal sequence, leave an analogous record of the
life history of a cancer inscribed in its genome.
EXPERIMENTAL PROCEDURES
The protocols for sequencing and bioinformatics analysis for identification of
somatic substitutions, indels, copy number changes and genomic rearrange-
ments are all described in the companion paper to this one (Nik-Zainal et al.,
2012). Estimates of normal cell contamination were derived by using the
ASCAT algorithm, based on analysis of the B allele fraction for heterozygous
germline SNPs for regions departing from diploidy in the tumor genome (Van
Loo et al., 2010). For PD4120a, this estimate includes a correction for the
fact that there is a tetraploid subclone.
For analyzing the subclonal structure of PD4120a and the other breast
cancer genomes, we developed several new bioinformatics algorithms. These
include methods for (1) phasing mutations with nearby heterozygous germline
SNPs; (2) phasing pairs of subclonal mutations in close proximity; (3) identi-
fying large-scale subclonal copy number variation (the Battenberg algorithm);
and (4) modeling the clusters of subclonal base substitutions from deep
coverage data by using Bayesian Dirichlet processes. These algorithms are
described in step-by-step detail in Extended Experimental Procedures.
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